Review Article|Articles in Press

Insulin Therapy Part 3: Cats

Published:March 09, 2023DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Veterinary Clinics: Small Animal Practice
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • McAllister M.
        Feline and canine diabetes prevalence in the USA. Banfield State of Pet Health.
        (Available at:)
        • Gilor C.
        • Niessen S.J.
        • Furrow E.
        • et al.
        What’s in a name? Classification of diabetes mellitus in veterinary medicine and why it matters.
        J Vet Intern Med. 2016; 30: 927-940
        • Krämer A.L.
        • Riederer A.
        • Fracassi F.
        • et al.
        Glycemic variability in newly diagnosed diabetic cats treated with the glucagon-like peptide-1 analogue exenatide extended release.
        J Vet Intern Med. 2020;
      1. Hewson-Hughes A.K., Gilham M.S., Upton S., et al., The effect of dietary starch level on postprandial glucose and insulin concentrations in cats and dogs, Br J Nutr, (106 Suppl), 2011, S105–S109.

        • Miki Y.
        • Mori A.
        • Hayakawa N.
        • et al.
        Evaluation of serum and urine 1,5-anhydro-D-glucitol and myo-inositol concentrations in healthy dogs.
        J Vet Med Sci. 2011; 73: 1117-1126
        • EGGLETON M.G.
        • SHUSTER S.
        Glucose and phosphate excretion in the cat.
        J Physiol. 1954; 124: 613-622
      2. Kruth S., Cowgill L., Renal glucose transport in the cat. (Abstract), Congress Proceedings ACVIM, Washington DC, 1982, 78.

        • Ward C.R.
        • Christiansen K.
        • Li J.
        • et al.
        Field efficacy and safety of protamine zinc recombinant human insulin in 276 dogs with diabetes mellitus.
        Domest Anim Endocrinol. 2020; 75: 106575
        • Maggiore A. Della
        • Nelson R.W.
        • Dennis J.
        • et al.
        Efficacy of protamine zinc recombinant human insulin for controlling hyperglycemia in dogs with diabetes mellitus.
        J Vet Intern Med. 2012; 26: 109-115
        • Clark M.
        • Thomaseth K.
        • Heit M.
        • et al.
        Pharmacokinetics and pharmacodynamics of protamine zinc recombinant human insulin in healthy dogs.
        J Vet Pharmacol Ther. 2012; 35: 342-350
        • Graham P.A.
        • Nash A.S.
        • McKellar Q.A.
        Pharmacokinetics of a porcine insulin zinc suspension in diabetic dogs.
        J Small Anim Pract. 1997; 38: 434-438
        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • et al.
        10-year follow-up of intensive glucose control in type 2 diabetes.
        N Engl J Med. 2008; 359: 1577-1589
        • Nathan D.M.
        • Genuth S.
        • Lachin J.
        • et al.
        • Diabetes Control and Complications Trial Research Group
        The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.
        N Engl J Med. 1993; 329: 977-986
      3. 6. glycemic targets: standards of medical care in diabetes-2018.
        Diabetes Care. 2018; 41: S55-S64
        • Gilor C.
        • Pires J.
        • Greathouse R.
        • et al.
        Loss of sympathetic innervation to islets of Langerhans in canine diabetes and pancreatitis is not associated with insulitis.
        Sci Rep. 2020; 10
        • Taborsky G.J.J.
        • Mundinger T.O.
        Minireview: the role of the autonomic nervous system in mediating the glucagon response to hypoglycemia.
        Endocrinology. 2012; 153: 1055-1062
        • Mundinger T.O.
        • Cooper E.
        • Coleman M.P.
        • et al.
        Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses.
        Am J Physiol Endocrinol Metab. 2015; 309: E246-E255
        • Gilor C.
        • Duesberg C.
        • Elliott D.A.
        • et al.
        Co-impairment of autonomic and glucagon responses to insulin-induced hypoglycemia in dogs with naturally occurring insulin-dependent diabetes mellitus.
        Am J Physiol Endocrinol Metab. 2020; 319: E1074-E1083
        • Martin G.J.
        • Rand J.S.
        Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
        J Feline Med Surg. 2001; 3: 23-30
        • Marshall R.D.
        • Rand J.S.
        • Morton J.M.
        Glargine and protamine zinc insulin have a longer duration of action and result in lower mean daily glucose concentrations than lente insulin in healthy cats.
        J Vet Pharmacol Ther. 2008;
        • Gilor C.
        • Ridge T.K.
        • Attermeier K.J.
        • et al.
        Pharmacodynamics of insulin detemir and insulin glargine assessed by an isoglycemic clamp method in healthy cats.
        J Vet Intern Med. 2010; 24: 870-874
        • Fink H.
        • Herbert C.
        • Gilor C.
        Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
        Domest Anim Endocrinol. 2018; 64
        • Sako T.
        • Mori A.
        • Lee P.
        • et al.
        Time-action profiles of insulin detemir in normal and diabetic dogs.
        Res Vet Sci. 2011; 90: 396-403
        • Roomp K.
        • Rand J.
        Evaluation of detemir in diabetic cats managed with a protocol for intensive blood glucose control.
        J Feline Med Surg. 2012; 14: 566-572
        • Roomp K.
        • Rand J.
        Intensive blood glucose control is safe and effective in diabetic cats using home monitoring and treatment with glargine.
        J Feline Med Surg. 2009; 11: 668-682
        • Gilor C.
        • Culp W.
        • Ghandi S.
        • et al.
        Comparison of pharmacodynamics and pharmacokinetics of insulin degludec and insulin glargine 300 U/mL in healthy cats.
        Domest Anim Endocrinol. 2019; 69
        • Gostelow R.
        • Forcada Y.
        • Graves T.
        • et al.
        Systematic review of feline diabetic remission: Separating fact from opinion.
        Vet J. 2014;
        • Weaver K.E.
        • Rozanski E.A.
        • Mahony O.M.
        • et al.
        Use of glargine and Lente insulins in cats with diabetes mellitus.
        J Vet Intern Med. 2006;[234:UOGALI]2.0.CO;2
        • Gostelow R.
        • Scudder C.K.
        • Hazuchova Y.
        • et al.
        One-Year Prospective Randomized Trial Comparing Efficacy of Glargine and Protamine Zinc Insulin in Diabetic Cats.
        J Vet Intern Med. 2017; : 1273
        • Saini N.K.
        • et al.
        Comparison of pharmacodynamics between insulin glargine 100 U/mL and insulin glargine 300 U/mL in healthy cats.
        Domest Anim Endocrinol. 2020; 75: 106595
        • Linari G.
        • Fleeman L.
        • Gilor C.
        • et al.
        Insulin glargine 300 units/mL for treatment of feline diabetes mellitus.
        J Feline Med Surg. 2022; : 168-176
        • Marshall R.D.
        • Rand J.S.
        • Morton J.M.
        Insulin glargine has a long duration of effect following administration either once daily or twice daily in divided doses in healthy cats.
        J Feline Med Surg. 2008;